FibroGen, Inc. (FGEN) Financials
Stock symbol FGEN is outdated, potentially delisted? Maybe it is available on other exchange?
Ticker FGEN was renamed to
KYNB
effective 2026-01-08.
FGEN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2025 | 137.0 million | 119.5 million |
| June 30, 2025 | 178.1 million | 359.1 million |
| March 31, 2025 | 165.2 million | 340.1 million |
| Dec. 31, 2024 | 214.5 million | 398.2 million |
FGEN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2025 | -1.9 million | 662000 |
| June 30, 2025 | 12.7 million | 1.9 million |
| March 31, 2025 | 2.7 million | 2.9 million |
| Dec. 31, 2024 | -30.6 million | 178000 |
FGEN Net Income
No data available :(
FGEN Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2025 | 118.0 million | 19.5 million | - |
| June 30, 2025 | 23.4 million | - | - |
| March 31, 2025 | 33.6 million | 73.4 million | - |
| Dec. 31, 2024 | 50.5 million | 90.2 million | 70000 |
FGEN Shares Outstanding
FGEN Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2025 | 8999 | 1.2 million | 5.3 million | - |
| June 30, 2025 | 13000 | 5.9 million | 7.1 million | - |
| March 31, 2025 | 16000 | 9.2 million | 8.1 million | - |
| Dec. 31, 2024 | 141000 | 1.5 million | -13.3 million | - |
FGEN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2025 | 1.1 million | -58000 |
| June 30, 2025 | 1.3 million | 85000 |
| March 31, 2025 | 2.7 million | 252000 |
| Dec. 31, 2024 | -123.3 million | -20.7 million |
FGEN Revenue by Segment
Graph available only for paid members. Upgrade to see it.
FGEN
Price: $9.71
52 week price:
Payout Ratio Range:
Earnings Per Share: -12.85 USD
P/E Ratio: -0.71
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.0 million
Ebitda: -33.4 millionMarket Capitalization: 37.1 million